Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Results bring welcome detail and no surprises
After the recent fundraising, there were no surprises in Destiny’s FY 2021 financials which...
Read moreNTCD-M3 competitors stumble while issue approved
With the recently announced fundraising approved at Destiny’s GM, and the competition to Destiny’s...
Read moreFundraising to bolster its positioning
Destiny have announced a conditional fundraising at 50p per share that includes a placing,...
Read moreVery welcome regulatory clarity
Destiny Pharma has announced details of positive feedback from the European Medicines Agency (EMA)...
Read moreM3’s profile rising further
In a spree of positive updates to start 2022, Destiny Pharma begins the year with the profile of...
Read more
Support on both fronts
Destiny’s most recently acquired Phase 3-ready product, the non-toxigenic Clostridioides difficile...
Read moreNew dermal collaboration on XF-73
Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its...
Read moreH1 2021 interims: still on track
Destiny's interim H1 2021 financial results were an upbeat and extensive update on the clinical...
Read moreXF-73 data maturing, like a fine wine
Destiny have released additional endpoint analyses after the positive headline announcement of the...
Read moreA glaring differential in validation
Recent transactions and the introduction of a new Act of the US Congress are further advancing the...
Read moreEncouraging AGM and M3 updates
Destiny’s recent announcement on the progress on its lead asset NTCD-M3 maintains the momentum that...
Read more- Prev
- 1 of 3 pages
- Next
Register to be first
Get research on the companies that interest you straight to your inbox
